Posts Tagged: "copaxone"

Other Barks & Bites for Wednesday, February 1st, 2017

This week, a patent battle between two American tech giants expands its scope to China, patents covering a well-known multiple sclerosis treatment were invalidated in U.S. district court and Trumpcare emerges as a possible trademarked moniker for the next incarnation of the country’s healthcare system, Disney files a patent application on evaluating human emotions while on amusement park rides, Ajit Pai holds his first open FCC meeting as Chairman and not surprisingly says he wants to reduce regulations, plus a whole lot more.

PTAB invalidates three patents covering Teva’s Copaxone, opens door for Mylan’s generic version

On Wednesday, August 24th, the Patent Appeal and Trial Board (PTAB) issued decisions in two inter partes review (IPR) filings made against patents owned by private Israeli firm Yeda Research & Development Co. The company is the tech transfer arm of the Weizmann Institute of Science, a public research university located in Rehovot, Israel. The IPRs, which were filed by American pharmaceutical developer Mylan Inc. (NYSE:MYL), resulted in the invalidation of all claims in both Yeda patents. About a week later, on September 1st, PTAB invalidated a third patent owned by Yeda after another IPR challenge was filed by Mylan.

Pharma Update: News for April 2014

What follows below is a review of some of the pharma news stories that caught my attention during the month of April 2014. Supreme Court Denies Teva’s Request for an Injunction Relating to Generic Copaxone® — Actavis Announces Celebrex® Patent Challenge Settlement — Actavis Net Revenue Increases 40% to $2.66 Billion in First Quarter 2014.

Teva Sues Mylan Over Multiple Sclerosis Drug COPAXONE®

Teva Pharmaceutical Industries Ltd. issued a press release last week discussing the abbreviated new drug application (ANDA) containing a Paragraph IV certification for COPAXONE® (glatiramer acetate injection), filed by Mylan Pharmaceuticals Inc. Teva announced that it has filed a lawsuit against Mylan Pharmaceuticals, Inc., Mylan Inc. and Natco Pharma Ltd. for patent infringement in the U.S. District Court for the…